PubTransformer

A site to transform Pubmed publications into these bibliographic reference formats: ADS, BibTeX, EndNote, ISI used by the Web of Knowledge, RIS, MEDLINE, Microsoft's Word 2007 XML.

Cardiotoxicity and Cardiac Monitoring During Adjuvant Trastuzumab in Daily Dutch Practice: A Study of the Southeast Netherlands Breast Cancer Consortium.

Abstract We assessed the incidence and timing of first cardiac events, impact on trastuzumab prescription, and role of left ventricular ejection fraction (LVEF) monitoring in daily practice of trastuzumab-treated patients with human epidermal growth receptor 2 (HER2)-positive early breast cancer.
PMID
Related Publications

Comparison of the long term cardiac effects associated with 9 and 52 weeks of trastuzumab in HER2-positive early breast cancer.

Role of Troponins I and T and N-Terminal Prohormone of Brain Natriuretic Peptide in Monitoring Cardiac Safety of Patients With Early-Stage Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer Receiving Trastuzumab: A Herceptin Adjuvant Study Cardiac Marker Substudy.

Cardiac Safety of Paclitaxel Plus Trastuzumab and Pertuzumab in Patients With HER2-Positive Metastatic Breast Cancer.

Cardiac toxicity of trastuzumab: experience at the Ghent Unversity Hospital, Belgium.

Cardiac Safety of Dual Anti-HER2 Therapy in the Neoadjuvant Setting for Treatment of HER2-Positive Breast Cancer.

Authors

Mayor MeshTerms
Keywords

Adjuvant trastuzumab

Cardiac monitoring

Cardiotoxicity

Daily practice

Journal Title the oncologist
Publication Year Start

 



PMID- 27009939
OWN - NLM
STAT- In-Process
DA  - 20160510
LR  - 20170501
IS  - 1549-490X (Electronic)
IS  - 1083-7159 (Linking)
VI  - 21
IP  - 5
DP  - 2016 May
TI  - Cardiotoxicity and Cardiac Monitoring During Adjuvant Trastuzumab in Daily Dutch 
      Practice: A Study of the Southeast Netherlands Breast Cancer Consortium.
PG  - 555-62
LID - 10.1634/theoncologist.2015-0230 [doi]
AB  - INTRODUCTION: We assessed the incidence and timing of first cardiac events,
      impact on trastuzumab prescription, and role of left ventricular ejection
      fraction (LVEF) monitoring in daily practice of trastuzumab-treated patients with
      human epidermal growth receptor 2 (HER2)-positive early breast cancer. METHODS:
      We included all patients with stage I-III breast cancer diagnosed in the early
      years (2005-2007) after the introduction of adjuvant trastuzumab in five
      hospitals in Southeast Netherlands. We studied the incidence and timing of
      cardiotoxicity in patients treated with adjuvant trastuzumab, using similar
      cardiac endpoints as in the Herceptin Adjuvant (HERA) trial. RESULTS: Of 2,684
      included patients, 476 (17.7%) had a HER2-positive tumor. Of these, 269 (56.9%)
      were treated with adjuvant chemotherapy, and of these, 230 (85.5%) also received 
      trastuzumab. Cardiotoxicity was observed in 29 of 230 patients (12.6%). Twenty of
      the 230 patients (8.7%) had symptomatic cardiotoxicity, defined as a drop in LVEF
      of at least 10 percentage points and to below 50%, accompanied by symptoms of
      congestive heart failure. Trastuzumab was definitely discontinued because of
      supposed cardiotoxicity in 36 patients (15.6%), of whom only 15 (6.5%) had a
      significant LVEF drop. Of the 36 patients who prematurely discontinued
      trastuzumab (including the 29 in whom cardiotoxicity was observed), 84.8% stopped
      in the first 6 months. No cardiac deaths were seen. CONCLUSION: In the first
      years after implementation of trastuzumab for treatment of early breast cancer,
      physicians frequently based their decision to discontinue treatment on patient
      symptoms apart from LVEF outcome. We suggest that focusing LVEF monitoring on the
      first 6 months might be more cost-effective without compromising patient safety. 
      Nonetheless, further research is needed. IMPLICATIONS FOR PRACTICE: Knowledge of 
      when cardiotoxicity occurs in daily practice will help shape the best follow-up
      method for cardiac monitoring in trastuzumab-treated patients with human
      epidermal growth receptor 2-positive early breast cancer. In the first years
      after implementation of trastuzumab for treatment of early breast cancer,
      physicians frequently based their decision to discontinue treatment on patient
      symptoms apart from left ventricular ejection fraction (LVEF) outcome. When
      cardiotoxicity was found in daily practice, it occurred mainly in the first 6
      months after start of trastuzumab. This study suggests that focusing LVEF
      monitoring on the first 6 months might be more cost-effective without
      compromising patient safety. This insight stresses the relevance of performing
      real-world analyses.
CI  - (c)AlphaMed Press.
FAU - Seferina, Shanly C
AU  - Seferina SC
AD  - Department of Medical Oncology, Maastricht University Medical Centre, Maastricht,
      The Netherlands GROW-School for Oncology and Developmental Biology, Maastricht
      University Medical Centre, Maastricht, The Netherlands.
FAU - de Boer, Maaike
AU  - de Boer M
AD  - Department of Medical Oncology, Maastricht University Medical Centre, Maastricht,
      The Netherlands GROW-School for Oncology and Developmental Biology, Maastricht
      University Medical Centre, Maastricht, The Netherlands.
FAU - Derksen, M Wouter
AU  - Derksen MW
AD  - Department of Internal Medicine, Maxima Medical Centre, Veldhoven, The
      Netherlands.
FAU - van den Berkmortel, Franchette
AU  - van den Berkmortel F
AD  - Department of Internal Medicine, Atrium Medical Centre Parkstad, Heerlen, The
      Netherlands.
FAU - van Kampen, Roel J W
AU  - van Kampen RJ
AD  - Department of Medical Oncology, Maastricht University Medical Centre, Maastricht,
      The Netherlands Department of Internal Medicine, Orbis Medical Centre, Sittard,
      The Netherlands.
FAU - van de Wouw, Agnes J
AU  - van de Wouw AJ
AD  - Department of Internal Medicine, VieCuri Medical Centre, Venlo, The Netherlands.
FAU - Joore, Manuela
AU  - Joore M
AD  - GROW-School for Oncology and Developmental Biology, Maastricht University Medical
      Centre, Maastricht, The Netherlands Department of Clinical Epidemiology and
      Medical Technology Assessment, Maastricht University Medical Centre, Maastricht, 
      The Netherlands.
FAU - Peer, Petronella G M
AU  - Peer PG
AD  - Department of Medical Oncology, Maastricht University Medical Centre, Maastricht,
      The Netherlands Radboud Institute for Health Science, Nijmegen, The Netherlands.
FAU - Voogd, Adri C
AU  - Voogd AC
AD  - Department of Medical Oncology, Maastricht University Medical Centre, Maastricht,
      The Netherlands GROW-School for Oncology and Developmental Biology, Maastricht
      University Medical Centre, Maastricht, The Netherlands Department of
      Epidemiology, Maastricht University Medical Centre, Maastricht, The Netherlands.
FAU - Tjan-Heijnen, Vivianne C G
AU  - Tjan-Heijnen VC
AD  - Department of Medical Oncology, Maastricht University Medical Centre, Maastricht,
      The Netherlands GROW-School for Oncology and Developmental Biology, Maastricht
      University Medical Centre, Maastricht, The Netherlands [email protected]
LA  - eng
PT  - Journal Article
DEP - 20160323
PL  - United States
TA  - Oncologist
JT  - The oncologist
JID - 9607837
SB  - IM
PMC - PMC4861356
OID - NLM: PMC4861356 [Available on 05/01/17]
OTO - NOTNLM
OT  - Adjuvant trastuzumab
OT  - Cardiac monitoring
OT  - Cardiotoxicity
OT  - Daily practice
EDAT- 2016/03/25 06:00
MHDA- 2016/03/25 06:00
CRDT- 2016/03/25 06:00
PHST- 2015/04/04 [received]
PHST- 2016/02/01 [accepted]
AID - theoncologist.2015-0230 [pii]
AID - 10.1634/theoncologist.2015-0230 [doi]
PST - ppublish
SO  - Oncologist. 2016 May;21(5):555-62. doi: 10.1634/theoncologist.2015-0230. Epub
      2016 Mar 23.